Drug intelligence / Profile preview

QSC303820

Development stage: Unknown
Lead developer: Quotient Sciences
Modality: Small Molecules
Administration: Oral

Overview

QSC303820 is an investigational drug currently undergoing Phase I clinical evaluation. Developed or managed by Quotient Sciences, the compound is being studied in a single-center, double-blind, randomized, placebo-controlled, dose-escalation trial to assess its safety, tolerability, and pharmacokinetics following single and multiple oral dose administration in healthy subjects. As the trial is registered under a deferral agreement (common in the UK for early-phase proprietary assets), specific details regarding its molecular target and therapeutic indication have not yet been publicly disclosed.

Beyond the preview

Go deeper on QSC303820.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QSC303820.

Explore the full profile